Abveris Deploys Second Berkeley Lights Beacon® System to Expand Single B Cell Antibody Discovery Capacity
CANTON, Mass., April 22, 2021 – Abveris, Inc.,...
In this webinar, Tracey will discuss the following topics:
• Rapid, efficient discovery of monoclonal antibodies against traditionally difficult targets, including cell surface receptors with complex specificity and functionality requirements
• The advantages of the Abveris single cell workflow (enabled by the Berkeley Lights Beacon®) as compared to other B cell screening platforms
• The advantages of incorporating genetically modified hyperimmune mouse models (DiversimAb™) into in vivo antibody discovery workflows that can greatly increase the likelihood of identifying antibodies binding non-immunodominant, functionally relevant epitopes
• A case study highlighting rapid antibody discovery against a cell surface receptor for which functional activity was paramount to success